CliffBio
small molecule

INDOMETHACIN

INDOMETHACIN

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameINDOMETHACIN
Active ingredientINDOMETHACIN
Strength25MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2024
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.